Genentech

Genentech, a US-based pharmaceutical preparation manufacturing company, reported its most recent carbon emissions for 2019. Its Scope 1 emissions were 76,815,000 kg CO2e, Scope 2 emissions (location-based) were 63,436,000 kg CO2e, and Scope 3 emissions totalled 73,599,000 kg CO2e, primarily from business travel (55,446,000 kg CO2e) and employee commutes (18,154,000 kg CO2e).

Looking back, Genentech's total location-based Scope 1 and 2 emissions have fluctuated, with 140,550,000 kg CO2e in 2019, down from 146,004,000 kg CO2e in 2018, and 153,189,000 kg CO2e in 2017. Emissions in 2016 were 174,001,000 kg CO2e, while in 2015 they were 169,954,000 kg CO2e. Earlier data indicates Scope 1 and 2 emissions of 163,437,000 kg CO2e in 2014, 161,595,000 kg CO2e in 2013, 162,086,000 kg CO2e in 2012, 169,635,000 kg CO2e in 2011, and 181,998,000 kg CO2e in 2010.

Genentech has committed to an absolute reduction target of 30% in CO2 emissions from its onsite energy use by 2020, against a 2010 baseline. Emissions data for Genentech is directly sourced from the organization itself, not cascaded from its parent company, Roche Holding AG, with the exception of SBTi targets which are cascaded from Roche Holding AG.